Immunohistochemistry reveals an increased proportion of MYC‐positive cells in subcutaneous panniculitis‐like T‐cell lymphoma compared with lupus panniculitis

Abstract

Our work demonstrates that MYC expression levels differ between these 2 histologic mimics and suggests that this important oncoprotein may play a role in the pathogenesis of SPTCL.

The pathophysiology and current treatments for the subcutaneous panniculitis‐like T cell lymphoma: An updated review

“…No presence of atypical T cells and low Ki‐67 proliferation index are two reliable histopathological features of LEP to distinguish these two diseases 21 . The expression of MYC, an oncoprotein as a transcription factor, was higher in SPTCL than that in lupus erythematosus panniculitis (LEP) 23 . This marker could be used for differential diagnosis as well.…”

“…21 The expression of MYC, an oncoprotein as a transcription factor, was higher in SPTCL than that in lupus erythematosus panniculitis (LEP). 23 This marker could be used for differential diagnosis as well. It is noteworthy that CD8+, βF1+, granzyme B+, and monoclonal T-cell clone, which are typical features in SPTCL, could also be expressed in LEP.…”

New developments in the pathology of malignant lymphoma. A review of the literature published from September–August 2017

“…The distinction between reactive and neoplastic lymphoproliferations of the skin is at times quite difficult. Fernandez-Pol et al [ 27 ] tried to find markers for the distinction between subcutaneous panniculitis-like T cell lymphoma (SPTCL) and lupus erythematosus panniculitis (LEP), lesions that have clinical and histological overlap. Using IHC for the MYC oncoprotein on 23 cases of SPTCL (1 CD8 negative) and 12 cases of LEP.…”